Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827979 · ClinicalTrials.gov registry record · Phase 1
Daratumumab and Belatacept for Desensitization
A Phase 1 study of Highly Sensitized Prospective Kidney Transplant Recipients, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04827979 is a Phase 1 study of Highly Sensitized Prospective Kidney Transplant Recipients that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04827979, a Phase 1 study of Highly Sensitized Prospective Kidney Transplant Recipients, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found for them or, they never receive a compatible donor, and die on waitlist. The purpose of this study is to find out whether two drugs, daratumumab (Darzalex®), and belatacept (Nulojix®), can make these kidney transplant candidates less sensitized, and make it easier and quicker to find a kidney donor for them.
Conditions Studied
Interventions
- BIOLOGICAL belatacept
- PROCEDURE Bone marrow aspiration
- BIOLOGICAL daratumumab
Study Locations (1)
California
- University of California at San Francisco Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04827979
The ClinicalTrials.gov registry entry for NCT04827979 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Highly Sensitized Prospective Kidney Transplant Recipients appearing as the primary indexed condition, and to 3 interventions - of which belatacept is the first listed.
NCT04827979 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04827979 about?
NCT04827979 is a clinical study titled "Daratumumab and Belatacept for Desensitization". Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors. Being "highly sensitized" means that they will likely have to wait a long time (more than 5 years) before an acceptable donor is found f...
What is the current status of trial NCT04827979?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2021-11-01. Estimated completion is 2028-04-30.
What conditions does trial NCT04827979 study?
This clinical trial studies the following conditions: Highly Sensitized Prospective Kidney Transplant Recipients.
What interventions are being tested in trial NCT04827979?
The interventions under investigation include: belatacept (BIOLOGICAL), Bone marrow aspiration (PROCEDURE), daratumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04827979?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04827979 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Highly Sensitized Prospective Kidney Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.